Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis

Annals of Laboratory Medicine

Volumn 32, Issue 2, 2012, Pages 105-112

  Lee, Jehoon ^a   Vasikaran, Samuel ^b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Bisphosphonates; Bone turnover markers; Fracture risk; Monitoring treatment; Osteoporosis

Indexed keywords

EID: 84859167960     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2012.32.2.105     Document Type: Review

References (63)

1. Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton U 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008; 42:467-75.
3. Lim S, Koo BK, Lee EJ, Park JH, Kim MH, Shin KH, et al. Incidence ofhip fractures in Korea. J Bone Miner Metab 2008;26:400-5.
4. Moon YW, Yoon BK, Min YK, Chang MJ, Jung SM, Um SJ, et al. Mortality, second fracture, and functional recovery after hip fracture surgery in elderly Koreans. Korean J Bone Metab 2008;15:41-7.
5. Lee SR, Kim SR, Chung KH, Ko DO, Cho SH, Ha YC, et al. Mortality and activity after hip fracture: a prospective study. J Korean Orthop Assoc 2005;40:423-7.
6. Kho DH, Kim KH, Shin JY, Lee JH, Kim DH. Postoperative mortality rate ofhip fracture in elderly patients. J Korean Fract See 2006;19:117-21.
7. Statistics Korea (https://www.index.go.kr/egams/stts/jsp/potal/stts/PO- STTS-ldxMain.jsp?idx-cd=1010&bbs=INDX-001) (Updated on Dec 2011)
8. Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos lnt 2011;22:1277-88.
9. Cooper C, Campion G, Melton U 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos lnt 1992;2:285-9.
10. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos lnt 2008;19:385-97.
11. Lee DY, Lim SJ, Moon YW, Min YK, Choi D, Yoon BK, Park YS. Determination ofan applicable FRAX model in Korean women. J Korean Med Sei 2010;25:1657-60.
12. Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P. Predictors of fractures in elderly women. Osteoporos lnt 2000;11:134-40.
13. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos lnt 2000;11:76-82.
14. van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, et al. Case-control analysis ofbone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 1996;312:482-3. (Pubitemid 26061239)
15. Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD. Serum type Icollagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000;27:283-6. (Pubitemid 30458823)
16. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers ofbone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY Study. J Bone Miner Res 2000;15: 1526-36. (Pubitemid 30484522)
17. Greenfield DM, Hannon RA, Eastell R. The association between bone turnover and fracture risk: The Sheffield Osteoporosis study. In: Eastell R, Baumann M, Hoyle N, Wieczorek L, eds. Bone markers - biochemical and clinical perspectives. Cachan: Lavoisier, 2001;225-6.
18. Garnero P, Cloos P, Sornay-Rendu E, Ovist P, Delmas PD. Type Icollagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2002; 17:826-33. (Pubitemid 34441899)
19. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 2005;20:579-87. (Pubitemid 40393065)
20. Bauer DC, Garnero P, Harrison SL, Cauley JA, Eastell R, Ensrud KE, et al. Biochemical markers ofbone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 2009;24:2032-8.
21. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos lnt 2011;22:391-420.
22. Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos lnt 2006;17:364-72.
23. Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following ankle fracture. Osteoporos lnt 1999;10:408-15.
24. Lane NE and Lukert B. The science and therapy of glucocorticoid-in-duced bone loss. Endocrinol Metab Clin North Am 1998;27:465-83. (Pubitemid 28285876)
25. Deodhar AA and Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996;35:309-22.
26. Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men (RACGP) http://www.racgp.org. au/guidelines/musculoskeletaldiseases/osteoporosis (Updated on Feb 2010)
27. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report ondietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
28. Glendenning P, Taranto M, Noble JM, Musk AA, Hammond C, Goldswain PR, et al. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem 2006;43:23-30. (Pubitemid 43105054)
29. Glendenning P, Laffer LL, Weber HK, Musk AA, Vasikaran SD. Parathyroid hormone ismore stable in EDTA plasma than in serum. Clin Chem 2002;48:766-7. (Pubitemid 34439109)
30. Chung SH, Kim TH, Lee HH. Relationship between Vitamin Dlevel and bone mineral density in postmenopausal women from Bucheon area. J Korean Society Osteoporos 2009;7:198-202.
31. Kim H,Ku SY, Kim SH, Choi YM, Moon SY, Kim JG. A study onvitamin D insufficiency in postmenopausal Korean women. J Korean Society Osteoporos 2003;1:12-21.
32. Park HM. Kim JG. Choi WH, Lim SK. Kim GS. The vitamin Dnutritional status of postmenopausal women in Korea. Korean J Bone Metab 2003; 10:47-55.
33. So JS and Park HM. Relationship between parathyroid hormone, vitamin D and bone turnover markers in Korean postmenopausal women. Korean J Obstet Gynecol 2004;47:153-60.
34. Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, et al. Bone turnover markers inthe management of postmenopausal osteoporosis. Clin Biochem 2009;42:929-42.
35. Koivula MK, Ruotsalainen V, Björkman M, Nurmenniemi S, Ikäheimo R, Savolainen K, et al. Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann Clin Biochem 2010;47:67-71.
36. Marin L, Koivula MK, Jukkola-Vuorinen A, Leino A, Risteli J. Comparison oftotal and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem 2011;48:447-51.
37. Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, et al. Effect ofdichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980;1:1043-7. (Pubitemid 10097866)
38. Fraser WD, Logue FC, Gallacher SJ, O'Reilly DS, Beastall GH, Ralston SH, et al. Direct and indirect assessment of the parathyroid hormone response to Pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Bone Miner 1991;12:113-21.
39. Chesnut CH 3rd and Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporosis lnt 1993;3(S3):S17-9.
40. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate- induced hypocalcemia: report of3 cases and review of literature. Endocr Pract 2006;12:48-53.
41. McCloskey EV, Yates AJ, Gray RE, Hamdy NA, Galloway J, Kanis JA. Diphosphonates and phosphate homeostasis in man. Clin Sei (Lond) 1988; 74:607-12.
42. Vasikaran SD, O'Doherty DP, McCloskey EV, Gertz B, Kahn S, Kanis JA. The effect ofalendronate on renal tubular reabsorption of phosphate. Bone Miner 1994;27:51-6.
43. Jodrell Dl, Iveson TJ, Smith lE.Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate. Lancet 1987; 1:622. (Pubitemid 17024237)
44. Chong G, Hoang T, Davis ID. Symptomatic hypocalcaemia following intravenous Pamidronate in cancer patients. Aust N Z J Med 1999;29:96-7. (Pubitemid 29136670)
45. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison ofnew biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
46. Schlosser K and Scigalla P. Biochemical markers assurrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest Suppl 1997;227:21-8. (Pubitemid 27163393)
47. Braga de Castro Machado A, Hannon R, Eastell R. Monitoring alendro- nate therapy for osteoporosis. J Bone Miner Res 1999;14:602-8. (Pubitemid 29153394)
48. Bell NH, Bilezikian JP, Bone HG 3rd, Kaur A, Maragoto A, Santora AC. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002; 87:2792-7. (Pubitemid 34655346)
49. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes inbiochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13: 1431-8. (Pubitemid 28418909)
50. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects ofbisphosphonate and estrogen therapy on free and peptidebound bone cross-links excretion. J Bone Miner Res 1995;10:641-9.
51. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue lnt 1994;54:26-9.
52. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue lnt 1998;63:363-8.
53. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab inpostmenopausal women with low bone mineral density. N Engl J Med 2005;354:821-31.
54. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70 mg compared with onceweekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51. (Pubitemid 41716229)
55. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8. (Pubitemid 41138965)
56. Body JJ, Gaich GA, Scheele WH, Kulkami PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35. (Pubitemid 35247036)
57. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects ofstrontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68. (Pubitemid 38133766)
58. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club, lnt J Clin Pract 2009;63:19-26.
59. Riggs BL, Melton U 3rd, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996; 18(S3):197S-201S. (Pubitemid 126352531)
60. Delmas PD and Seeman E. Changes inbone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599-604. (Pubitemid 38393794)
61. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos lnt 2000;11(S6):S66-76.
62. Hannon R and Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos lnt 2000; 11 (S6):S30-44.
63. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. Development ofan algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006;22:61-6. (Pubitemid 43106908)